Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 37 (3), 1191-5

High Mobility Group Box 1: A Potential Therapeutic Target for Systemic Lupus Erythematosus

Affiliations
Review

High Mobility Group Box 1: A Potential Therapeutic Target for Systemic Lupus Erythematosus

Hai-Feng Pan et al. Mol Biol Rep.

Abstract

High Mobility Group Box 1 (HMGB1) is a nuclear protein participating in chromatin architecture and transcriptional regulation. Recently, there is increasing evidence that HMGB1 contributes to the pathogenesis of chronic inflammatory and autoimmune diseases due to its pro-inflammatory and immunostimulatory properties. Elevated expression of HMGB1 was found in the sera of patients and mice with systemic lupus erythematosus (SLE). In addition, it has been shown that HMGB1 may act as a proinflammatory mediator in antibody-induced kidney damage in SLE. All theses findings suggest that HMGB1 have important biological effects in autoimmunity that might be a promising therapeutic target for SLE. In this review, we will briefly discuss the biological features of HMGB1 and summarize recent advances on the role of HMGB1 in the pathogenesis and treatment of SLE.

Similar articles

See all similar articles

Cited by 12 PubMed Central articles

See all "Cited by" articles

References

    1. EMBO J. 2003 Oct 15;22(20):5551-60 - PubMed
    1. Am J Physiol Cell Physiol. 2006 Dec;291(6):C1318-25 - PubMed
    1. FEBS Lett. 1980 Dec 29;122(2):264-70 - PubMed
    1. Clin Exp Immunol. 1998 Feb;111(2):402-7 - PubMed
    1. J Rheumatol. 2000 Oct;27(10):2489-93 - PubMed

Publication types

Feedback